Background: The HUMBA Trial investigated whether a culturally tailored multifaceted dietary intervention and/or probiotic capsules (Lactobacillus rhamnosus GG, Bifidobacterium lactis BB12) in obese pregnant women would reduce excessive gestational weight gain (EGWG) and optimise infant birthweight.
DIFFERENCES IN THE PLASMA METABOLOME CAN BE OBSERVED IN OBESE PREGNANT WOMEN~10 WEEKS PRIOR TO CLINICAL DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS
Gestational diabetes mellitus (GDM) affects approximately 1 in 7 pregnancies worldwide. GDM is typically diagnosed at 24-28 weeks gestation. By this time the fetus may have been exposed to high levels of maternal glucose and other metabolites, and already be excessively large. The best approach to reduce the consequences of GDM may be to identify women at high risk and intervene early. Current early pregnancy screening tools are of limited efficacy. The metabolome is the detectable collection of low-molecular weight compounds which provides information from endogenous and exogenous sources. We aimed to explore the maternal metabolome in early pregnancy in the search for metabolites associated with later GDM development.
Methods: Early pregnancy plasma (<18 weeks) was obtained from 139 obese participants in the Healthy Mums and Babies (HUMBA) trial. GDM was diagnosed by international criteria. The plasma metabolome was analysed using gas chromatography-mass spectrometry. Mann-Whitney tests determined if there was a significant relationship between the metabolites and GDM. P<0.05 was considered statistically significant, and false discovery rates (FDR) were calculated.
Results: Of 255 metabolites detected, 14 were significantly different between participants with and without GDM. 2-hydroxybutyric acid was the most significant metabolite, found to be higher in women who developed GDM (P-value=0.001; FDR=0.15). Area under the receiver operating characteristic curve (95% confidence interval) for 2-hydroxybutyric acid was 0.68 (0.59-0.78).
Conclusions: Differences in the early pregnancy plasma metabolome could be detected in obese pregnant women from South Auckland, New Zealand~10 weeks prior to clinical diagnosis of GDM. Background: Early-life microbial colonisation is believed to play a role in immune programming and health, yet the evidence regarding the origins, timing and significance of the neonatal microbiome remains inconclusive due to concerns around sample integrity, confounding factors & contamination.
SEEDING OF THE FETAL GUT MICROBIOME: INSIGHTS INTO ORIGINS AND SIGNIFICANCE
Methods: Placental, amniotic fluid, first-pass meconium and cord blood samples were collected from 50 elective Caesarean section deliveries. An optimised sampling and analysis protocol was employed to minimise/control for contamination, allowing characterisation of the fetal gut microbiome and its relationship with maternal parameters, short chain fatty acid (SCFA) levels and inflammation.
Results: All meconium samples contained detectable levels of bacterial DNA and the immunomodulatory SCFAs acetate and propionate, confirming the hypothesis that the fetal gut is inoculated with bacteria in utero. At the phylum level, meconium was dominated by Proteobacteria and Firmicutes. Acinetobacterknown to be allergy protective -was the most abundant genus (found in 95% of samples), followed by Pelomonas (88%). Importantly, these two genera have been found in the core nonpregnant endometrial microbiome, but not paired vaginal samples. Lactobacillus (which dominates the vaginal microbiome) was found in only 5 samples. Maternal diabetes, intra-amniotic inflammation and SCFA levels were all associated with altered meconium microbiome.
Conclusions: Seeding of the fetal gut microbiome commences prenatally and may originate from the endometrial microbiome present at time of conception; vaginal contribution appears minimal. Maternal metabolic health and intrauterine inflammation may influence fetal immune programming via modulation of the fetal microbiome and immunomodulatory SCFAs.
